PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 1, 2013, Pages 189-199

  Patel, Atish ^a   Tiwari, Amit K ^a,c   Chufan, Eduardo E ^b   Sodani, Kamlesh ^a   Anreddy, Nagaraju ^a   Singh, Satyakam ^a   Ambudkar, Suresh V ^b   Stephani, Ralph ^a   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c TUSKEGEE UNIVERSITY   (United States)

Author keywords

ABC transporter; ABCB1; Fibroblast growth factor receptor; Multidrug resistance; PD173074; Tyrosine kinase inhibitor

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 (4,5 DIMETHYLTHIAZOL YL) 2,5 DIPHENYLLAPATINIBRAZOLIUM BROMIDE; ABC TRANSPORTER; ABCC1 PROTEIN; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; BROMINE DERIVATIVE; COLCHICINE; IODOARYLAZIDOPRAZOSIN I 125; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RADIOISOTOPE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BINDING SITE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIZATION; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; HYDROLYSIS; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; AFFINITY LABELS; ALLOSTERIC REGULATION; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COLCHICINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; HYDROLYSIS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEINS; TUBULIN MODULATORS; VINCRISTINE;

EID: 84879795172     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2184-z     Document Type: Article

References (49)

1. Calcagno AM, Ambudkar SV (2010) Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol Biol 596:77-93. doi: 10.1007/978-1-60761-416-6-5
2. Choi CH (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 5:30. doi: 10.1186/1475-2867-5-30
3. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11(7):1156-1166. doi: 10.1101/gr.184901
4. Fardel O, Lecureur V, Guillouzo A (1996) The P-glycoprotein multidrug transporter. Gen Pharmacol 27(8):1283-1291. doi: 10.1016/S0306-3623(96)00081-X
5. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-234. doi: 10.1038/nrd1984
6. Doyle LA, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22(47):7340-7358. doi: 10.1038/sj.onc.1206938
7. Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD (2003) Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63(14):4048-4054
8. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627. doi: 10.1146/annurev.med.53.082901.103929
9. Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22(47):7537-7552. doi: 10.1038/sj.onc.1206953
10. Sodani K, Patel A, Kathawala RJ, Chen ZS (2012) Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer 31(2):58-72. doi: 10.5732/cjc.011.10329
11. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11(4):265-283. doi: 10.1016/S0928-0987(00)00114-7
12. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398. doi: 10.1146/annurev. pharmtox.39.1.361
13. Hollt V, Kouba M, Dietel M, Vogt G (1992) Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 43(12):2601-2608
14. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8(2):125-140
15. van Zuylen L, Sparreboom A, van der Gaast A, van der Burg ME, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J (2000) The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 6(4):1365-1371
16. Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K (1999) BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma. Br J Cancer 80(8):1190-1196. doi: 10.1038/sj.bjc.6690485
17. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD (1998) Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16(9):2964-2976
18. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA (1999) Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290(2):854-862
19. Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R (1999) The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol 128(2):403-411. doi: 10.1038/sj.bjp.0702807
20. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61(2):749-758
21. Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8(5):411-424
22. Leonard GD, Polgar O, Bates SE (2002) ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs 3(11):1652-1659
23. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS (2009) Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 78(2):153-161. doi: 10.1016/j.bcp.2009.04.002
24. Shen T, Kuang YH, Ashby CR, Lei Y, Chen A, Zhou Y, Chen X, Tiwari AK, Hopper-Borge E, Ouyang J, Chen ZS (2009) Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS ONE 4(10):e7520. doi: 10.1371/journal.pone.0007520
25. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68(19):7905-7914. doi: 10.1158/0008-5472.CAN-08-0499
26. Knights V, Cook SJ (2010) De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125(1):105-117. doi: 10.1016/j.pharmthera. 2009.10.001
27. Jeffers M, LaRochelle WJ, Lichenstein HS (2002) Fibroblast growth factors in cancer: therapeutic possibilities. Expert Opin Ther Targets 6(4):469-482. doi: 10.1517/14728222.6.4.469
28. Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C, Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem 40(15):2296-2303. doi: 10.1021/jm970367n
29. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, Eliseenkova AV, Green D, Schlessinger J, Hubbard SR (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17(20):5896-5904. doi: 10.1093/emboj/17.20.5896
30. Akiyama S, Seth P, Pirker R, FitzGerald D, Gottesman MM, Pastan I (1985) Potentiation of cytotoxic activity of immunotoxins on cultured human cells. Cancer Res 45(3):1005-1007
31. Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE (2008) Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 75(6):1302-1312. doi: 10.1016/j.bcp.2007.12.001
32. Muller M, Yong M, Peng XH, Petre B, Arora S, Ambudkar SV (2002) Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry 41(31):10123-10132. doi: 10.1021/bi026075s
33. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254. doi: 10.1016/0003-2697(76)90527-3
34. Sodani K, Tiwari AK, Singh S, Patel A, Xiao ZJ, Chen JJ, Sun YL, Talele TT, Chen ZS (2012) GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol 83(12):1613-1622. doi: 10.1016/j.bcp.2012.02.028
35. Ambudkar SV (1998) Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. Methods Enzymol 292:504-514. doi: 10.1016/S0076-6879(98)92039-0
36. Sauna ZE, Ambudkar SV (2000) Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. Proc Natl Acad Sci USA 97(6):2515-2520
37. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67(22):11012-11020. doi: 10.1158/0008-5472.CAN-07-2686
38. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu L, Kaddoumi A, Gallo JM, Chen ZS (2013) Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett 328(2):307-317. doi: 10.1016/j.canlet.2012.10.001
39. Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, Ma XX, To KK, Ambudkar SV, Chen ZS, Fu LW (2010) Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 70(20):7981-7991. doi: 10.1158/0008-5472.CAN-10-0111
40. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, Keri G (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587(2-3):318-325. doi: 10.1016/S0925-4439(02)00095-9
41. Shukla S, Robey RW, Bates SE, Ambudkar SV (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37(2):359-365. doi: 10.1124/dmd.108.024612
42. Tong XZ, Wang F, Liang S, Zhang X, He JH, Chen XG, Liang YJ, Mi YJ, To KK, Fu LW (2012) Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol 83(5):586-597. doi: 10.1016/j.bcp.2011.12.007
43. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, Lemoine NR, Stamp GW, Aboagye EO, Seckl MJ (2009) The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 69(22):8645-8651. doi: 10.1158/0008-5472.CAN-09-1576
44. Friesel RE, Maciag T (1995) Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 9(10):919-925
45. Song S, Wientjes MG, Gan Y, Au JL (2000) Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 97(15):8658-8663. doi: 10.1073/pnas.140210697
46. Pardo OE, Arcaro A, Salerno G, Tetley TD, Valovka T, Gout I, Seckl MJ (2001) Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene 20(52):7658-7667. doi: 10.1038/sj.onc.1204994
47. Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout IT, Sebire N, Marais R, Downward J, Seckl MJ (2006) FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 25(13):3078-3088. doi: 10.1038/sj.emboj.7601198
48. Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ (1999) Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 17(2):121-135
49. Liu KJ, He JH, Su XD, Sim HM, Xie JD, Chen XG, Wang F, Liang YJ, Singh S, Sodani K, Talele TT, Ambudkar SV, Chen ZS, Wu HY, Fu LW (2013) Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Int J Cancer 132(1):224-235. doi: 10.1002/ijc.27649